New Alzheimer’s therapy restores neurotransmission
Porosome Therapeutics has shared key advancements in its disease-modifying neurological platform, which it claims will transform Alzheimer’s Disease (AD) research and treatment by offering a new approach that goes beyond symptom management.
The company has demonstrated a relatively rapid reduction of the Alzheimer’s pathology in AD human brain organoids treated with its principal therapy, and shown a significant reduction of the Tau protein.
Researchers introduced healthy porosomes – neuronal secretory nanomachines – into diseased neurons to target the root causes of AD.
By restoring the neuron’s secretory and metabolic systems, Porosome Therapeutics’ approach addresses the cellular function of AD rather than traditional symptom management.
“Unlike therapies that merely dissolve beta amyloid plaques, our platform directly targets the core biological dysfunctions of Alzheimer’s, restoring both neurotransmission and metabolic integrity,” said Guillermo Marmol, CEO, Porosome Therapeutics. “Given Alzheimer’s is a serious and life-threatening disease with no effective treatment options, and based on our ability to deliver quantifiable, biomarker-driven improvements, including Tau reduction and disease reversal in human brain organoids, we are actively exploring the FDA’s accelerated approval pathway.”
In recent studies, the company’s approach to porosome restoration has been shown to significantly reduce Tau protein levels – a key FDA-approved biomarker of Alzheimer’s.
In a complementary development, the company is leveraging artificial intelligence (AI) to design proprietary decoy peptides that target and neutralise the toxic beta amyloid peptide (1-42), which is known for disrupting protein-protein interactions within the neuronal porosome complex and impairing neurotransmitter release.
These specially designed AI-decoys bind more strongly to the beta amyloid (1-42), diverting the peptide from interfering with essential porosome functions.
Diana Turner, Senior Digital Content Editor, DDW
